Health Economics for Non-Health-Economists

THE CONTENT
Health-economic evidence has become a critical driver of market access success. Without robust data on cost-effectiveness and budget impact, pharma and medtech products risk facing significant hurdles in gaining reimbursement and access.

This course offers a clear and practical introduction to health economic evaluations and budget impact analysis, tailored specifically for non-health-economists. You will learn the fundamentals needed to understand, interpret, and communicate economic value. This will equip you to make better-informed decisions and engage more effectively in discussions around pricing, reimbursement, and access.

Whether your work is in development, medical affairs, market access, or marketing, this course will help you integrate health economic thinking into product strategy and value communication!

THE EXPERT
Prof. Dr Lieven Annemans is one of Europe’s most respected experts in health economics.

WHAT YOU WILL LEARN

• The logic and mathematics behind QALYs, ICERs, decision trees and Markov models.
• How external stakeholders use and challenge health economic evidence.
• How to distinguish good from bad health economic evaluation studies (of your brand or its competitors).
• Key principles of cost-effectiveness analysis and Budget Impact Analysis.
• The role of health economic evaluations in clinical research, pricing & reimbursement decisions, and post-launch.